Ozempic vs. Zepbound: Which Is Better? Side-by-Side Comparison

If your main goal is to lose weight and keep it off, Zepbound is generally the better choice. It’s specifically FDA-approved for chronic weight management and has demonstrated substantial weight loss in clinical trials.

However, if your main goal is to control blood sugar while managing type 2 diabetes, Ozempic may be the better option because it’s specifically approved for diabetes treatment.

So, which one should you choose? It depends on what you’re trying to accomplish and your medical history. Ozempic contains semaglutide, while Zepbound contains tirzepatide, and they work differently in the body.

Ultimately, the best choice is the medication that addresses your health priorities while being safe and appropriate for your individual needs.

DFWPMA offers GLP-1 prescription evaluations in Texas and can prescribe GLP-1 medications to eligible patients when medically appropriate, subject to medication availability.

DFWPMA offers in-person GLP-1 prescription evaluations in Texas and can prescribe GLP-1 medications at a DFWPMA location across Texas to eligible patients when medically appropriate, subject to medication availability.

Our primary care providers and endocrinologists also offer ongoing care to monitor potential side effects, address health concerns, and support patients throughout GLP-1 treatment. DFWPMA does not currently offer online GLP-1 prescriptions, an in-person evaluation is required.

Book an appointment online or call (903) 957-0082 to contact our scheduling team.

Get Prescriptions for GLP-1 Medications at a DFWPMA Location Near You!

📍 GLP-1 Prescription Providers in Fort Worth, TX

1220 W Presidio St, Fort Worth, TX 76102

Book an Appointment at Our Fort Worth Location →
📍 GLP-1 Prescription Providers in Frisco, TX

7589 Preston Rd., Suite 900, Frisco, TX 75034

Book an Appointment at Our Frisco Location →
📍 GLP-1 Prescription Providers in Sherman, TX

425 N Highland Ave., Suite 260, Sherman, TX 75092

Book an Appointment at Our Sherman Location →
📞 Call DFWPMA to Schedule

Speak with our scheduling team about GLP-1 prescription evaluations, provider availability, and appointments.

Call Us → (903) 957-0082

We accept many major insurance plans. Not sure if your plan is accepted?

Call (903) 957-0082 and our team can help verify coverage.

What Is Ozempic?

Ozempic (semaglutide) is a prescription GLP-1 receptor agonist primarily used to improve blood sugar control in adults with type 2 diabetes. It also reduces the risk of major cardiovascular events in adults with type 2 diabetes and established cardiovascular disease, and certain kidney and cardiovascular outcomes in adults with type 2 diabetes and chronic kidney disease.

Ozempic works by stimulating glucose-dependent insulin secretion, reducing glucagon secretion, and slowing gastric emptying. It can also reduce appetite and promote weight loss, although Ozempic is not FDA-approved specifically for weight management.

ozempic

What Is Zepbound?

Zepbound (tirzepatide) is a prescription medication approved for chronic weight management in adults with obesity or overweight with at least one weight-related medical condition. It is also approved to treat moderate to severe obstructive sleep apnea in adults with obesity.

Zepbound activates two hormone receptors: glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1). This dual action helps regulate appetite, reduce food intake, and promote substantial weight loss. Although tirzepatide also improves blood sugar regulation, Zepbound is not specifically FDA-approved to treat type 2 diabetes.

Zepbound

Ozempic vs. Zepbound: Side by Side Comparison

Ozempic and Zepbound differ primarily in their approved medical uses, active ingredients, and weight-loss effectiveness. Ozempic is designed primarily for type 2 diabetes management, while Zepbound is designed for chronic weight management and treatment of certain patients with obstructive sleep apnea. Both require medical evaluation and ongoing monitoring.
Comparison Ozempic Zepbound
Manufacturer Novo Nordisk Eli Lilly and Company
Pricing Manufacturer self-pay offers:
  • Introductory Offer: Starting at $199/month for eligible new injection patients during a limited promotional period.
  • Standard Injection Offers: Approximately $349–$499/month, depending on dose and eligibility.
  • Oral Formulation: Self-pay offers starting at $149/month.
Retail prices may be higher.
Manufacturer self-pay options:
  • Starting Price: $299/month for the 2.5 mg starting dose.
  • Higher Doses: Monthly costs increase depending on prescribed dosage.
  • Eligibility: Pricing depends on delivery device and manufacturer program requirements.
Retail prices may be higher.
Insurance Coverage
  • Commercial Insurance: Many plans cover Ozempic for eligible patients with type 2 diabetes.
  • Medicare Part D: Coverage may be available for medically eligible beneficiaries.
  • Weight Loss Alone: Generally not covered because Ozempic is not approved specifically for weight management.
  • Commercial Insurance: Some plans cover Zepbound for eligible patients with obesity or other approved indications.
  • Prior Authorization: Medical eligibility and documentation may be required.
  • Medicare: Coverage depends on the approved indication, applicable program rules, and individual plan.
Main Purpose Improve blood sugar control in adults with type 2 diabetes. Long-term weight loss and weight maintenance in eligible adults with obesity or overweight.
Secondary Purposes
  • Cardiovascular Protection: Reduce major cardiovascular events in adults with type 2 diabetes and established cardiovascular disease.
  • Kidney Protection: Reduce certain kidney and cardiovascular risks in adults with type 2 diabetes and chronic kidney disease.
  • Sleep Apnea: Treat moderate to severe obstructive sleep apnea in adults with obesity.
  • Metabolic Health: May improve blood sugar regulation and other metabolic measures.
Active Ingredient Semaglutide, a GLP-1 receptor agonist. Tirzepatide, a dual GIP and GLP-1 receptor agonist.
Benefits
  • Blood Sugar Control: Lowers blood glucose and HbA1c.
  • Weight Management: May promote weight loss.
  • Cardiovascular Health: Reduces certain cardiovascular risks in eligible adults with type 2 diabetes.
  • Kidney Health: Provides demonstrated benefits in specified patients with diabetic chronic kidney disease.
  • Weight Loss: Produces substantial average weight reduction in eligible adults.
  • Appetite Regulation: Reduces hunger and food intake.
  • Metabolic Health: May improve weight-related metabolic measures.
  • Sleep Apnea: Reduces obstructive sleep apnea severity in eligible adults with obesity.
Potential Health Risks
  • Pancreatitis: Potential acute pancreatic inflammation.
  • Gallbladder Problems: Including gallstones and gallbladder inflammation.
  • Kidney Injury: Possible dehydration-related acute kidney injury.
  • Eye Complications: Possible worsening of diabetic retinopathy.
  • Thyroid Warning: Boxed warning for thyroid C-cell tumors observed in rodents.
  • Pancreatitis: Potential acute pancreatic inflammation.
  • Gallbladder Problems: Including gallstones and gallbladder inflammation.
  • Kidney Injury: Possible dehydration-related acute kidney injury.
  • Gastrointestinal Reactions: Potentially severe digestive symptoms.
  • Thyroid Warning: Boxed warning for thyroid C-cell tumors observed in rodents.
Weight Loss Potential Can produce clinically meaningful weight loss, but results depend on dosage, patient characteristics, and treatment duration. Ozempic is not approved specifically for weight loss. Approximately 15%–21% average body-weight reduction in major trials involving adults without diabetes, depending on dosage and study conditions. Individual results vary.
Administration
  • Injection: Subcutaneous injection once weekly.
  • Oral Tablet: Once-daily oral formulation with specific administration instructions.
  • Injection: Subcutaneous injection once weekly.
  • Injection Sites: Abdomen, thigh, or upper arm.
  • Available Forms: Different injection devices and vial presentations.
Dosing Considerations
  • Starting Injection Dose: Typically 0.25 mg weekly.
  • Dose Escalation: Gradual increases based on treatment response and tolerability.
  • Oral Dosing: Follows a separate daily dosing schedule.
  • Starting Dose: Typically 2.5 mg weekly.
  • Dose Escalation: Gradual increases according to response and tolerability.
  • Maintenance Dose: Selected according to treatment indication and individual response.
Who May Benefit Most? Adults with type 2 diabetes, particularly those who also meet the criteria for its cardiovascular or kidney risk-reduction indications. Adults with obesity or qualifying overweight who need long-term weight management, including eligible patients with obesity-related obstructive sleep apnea.
How Fast Does It Work?
  • Blood Sugar: Improvements may begin within the first weeks.
  • HbA1c: Reductions are generally assessed over approximately 3 months.
  • Weight Loss: Typically develops gradually over several months.
  • Appetite: Changes may begin within the first several weeks.
  • Initial Weight Loss: May become noticeable within several weeks.
  • Substantial Weight Loss: Generally develops over several months, with major trials assessing outcomes at approximately 72 weeks.
Potential Side Effects
  • Digestive: Nausea, vomiting, diarrhea, abdominal pain, and constipation.
  • Timing: Gastrointestinal symptoms frequently occur when starting treatment or increasing dosage.
  • Digestive: Nausea, diarrhea, vomiting, constipation, abdominal discomfort, and indigestion.
  • Other Effects: Fatigue and injection-site reactions.
  • Timing: Gastrointestinal symptoms frequently occur during dose escalation.
Information Accuracy Disclaimer: Pricing, insurance coverage, medication availability, and other details may change over time. The information presented in this comparison reflects available information as of November 6, 2026. For the most current details, consult the medication manufacturers, your insurance provider, or a qualified healthcare professional. Important: Both medications carry a boxed warning concerning thyroid C-cell tumors observed in rodents; whether they cause these tumors in humans is unknown. Neither should be used by patients with a personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2 (MEN 2). Treatment selection requires an individualized medical assessment. Weight-loss evidence: In the SURMOUNT-5 clinical trial, tirzepatide produced an average 20.2% body-weight reduction compared with 13.7% for semaglutide after 72 weeks in adults with obesity or overweight without diabetes. However, this study compared Zepbound with Wegovy, not Ozempic. Therefore, these percentages should not be interpreted as a direct Ozempic-versus-Zepbound comparison. Sources: Medical Disclaimer: This article is intended for informational and educational purposes only and provides a general comparison of Ozempic and Zepbound. It is not a substitute for professional medical advice, diagnosis, or treatment. The safety, effectiveness, and suitability of either medication depend on individual medical history, health conditions, and treatment goals. For a comprehensive evaluation and personalized treatment recommendations, consult a qualified healthcare provider before starting, changing, or discontinuing either medication.

Related Ozempic Content

Zepbound Related Content